1. Trance to… Transition

12. F rom T est T ube to P atients

14. Drug Development Chart A Long Road Towards Innovation

21. Drugs Approved by FDA Eradication of Helicobacter pylori 28-Sep-06 biskalcitrate potassium, metronidazole and tetracycline Exposure to Organophosphorous Nerve Agents 28-Sep-06 atropine and pralidoxime chloride Prevention of Pregnancy 17-Mar-06 drospirenone and ethinyl estradiol Prevention of Influenza 05-Oct-06 Influenza Virus Vaccine Irritability Associated with Autistic Disorder 06-Oct-06 risperidone Cutaneous T-cell Lymphoma 06-Oct-06 vorinostat Chronic Obstructive Pulmonary Disease 06-Oct-06 arformoterol tartrate Non-Small Cell Lung Cancer 11-Oct-06 bevacizumab Zollinger-Ellison Syndrome 11-Oct-06 esomeprazole magnesium Head and Neck Cancer 17-Oct-06 docetaxel) Type 2 Diabetes 17-Oct-06 sitagliptin phosphate Bipolar Depression 20-Oct-06 Allergic Rhinitis Allergic Rhinitis 20-Oct-06 ciclesonide Atopic Dermatitis 20-Oct-06 desonide Chronic Hepatitis B 25-Oct-06 telbivudine Genital and Perianal Warts 31-Oct-06 Veregen Angina Pectoris 02-Nov-06 nitroglycerin Acne 07-Nov-06 clindamycin phosphate and tretinoin Indication Approval date Molecule

22. Drugs Approved by FDA Prevention of Cervical Cancer other HPV-related Diseases 08-Jun-06 Quadrivalent Human Papillomavirus Asthma 08-Jun-06 fluticasone propionate and salmeterol Parkinson’s Disease 14-Jun-06 selegiline hydrochloride Moderate-to-Severe Pain 23-Jun-06 oxymorphone Human Immunodeficiency Virus (HIV) 23-Jun-06 darunavir) Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (Ph+ALL) 28-Jun-06 dasatinib Wet Age-Related Macular Degeneration 30-Jun-06 ranibizumab Topical Local Anesthesia 06-Jul-06 lidocaine and tetracaine HIV-1 Infection 12-Jul-06 efavirenz, emtricitabine and tenofovir disoproxil fumarate Contraception 18-Jul-06 etonogestrel Hunter Syndrome 24-Jul-06 idursulfase Seborrheic Dermatitis 28-Jul-06 ketoconazole Type 2 Diabetes 31-Jul-06 pioglitazone HCl and glimepiride Epilepsy 31-Jul-06 levetiracetam Ankylosing Spondylitis 28-Aug-06 adalimumab Prevention of Invasive Fungal Infections 15-Sep-06 posaconazole Mild-to-Moderate Atopic Dermatitis 19-Sep-06 desonide Glaucoma and Ocular Hypertension 21-Sep-06 travoprost Primary Generalized Tonic-Clonic Seizures 22-Sep-06 lamotrigine Breakthrough Pain in Patients with Cancer 25-Sep-06 fentanyl Metastatic Colorectal Cancer 27-Sep-06 panitumumab Acne 07-Nov-06 clindamycin phosphate and tretinoin Indication Approval date Molecule

23. Drugs Approved by FDA Heartburn/GERD, Erosive Esophagitis, Duodenal & Gastric Ulcers 27-Feb-06 omeprazole/sodium bicarbonate Major Depressive Disorder 28-Feb-06 selegiline Prevention of Pregnancy 17-Mar-06 drospirenone and ethinyl estradiol Colon Cleansing prior to Colonoscopy 17-Mar-06 sodium phosphate monobasic monohydrate/sodium phosphate dibasic anhydrous Heartburn/GERD, Erosive Esophagitis, Duodenal & Gastric Ulcers 27-Mar-06 omeprazole, sodium bicarbonate and magnesium hydroxide Attention Deficit Hyperactivity Disorder 06-Apr-06 methylphenidate Alcohol Dependence 13-Apr-06 naltrexone Patent Ductus Arteriosus 13-Apr-06 ibuprofen lysine Pompe Disease 28-Apr-06 alglucosidase alfa Myelodysplastic Syndromes 03-May-06 decitabine Acne Vulgaris 08-May-06 minocycline Smoking Cessation 11-May-06 varenicline Chemotherapy-induced Nausea and Vomiting 15-May-06 nabilone Parkinson’s Disease 17-May-06 rasagiline Acute Postoperative Pain 23-May-06 fentanyl Prevention of Pregnancy 25-May-06 levonorgestrel/ethinyl estradiol and ethinyl estradiol Prevention of Shingles 25-May-06 Zoster Vaccine Live Rosacea 26-May-06 doxycycline Growth Disorders 30-May-06 somatropin [rDNA origin] Asthma and other Inflammatory Conditions in Children 01-Jun-06 prednisolone sodium phosphate Facial Wrinkles and Folds 05-Jun-06 hyaluronic acid Acne 07-Nov-06 clindamycin phosphate and tretinoin Indication Approval date Molecule

24. Drugs Approved by FDA Prevention of Postmenopausal Osteoporosis 04-Jan-06 estradiol/levonorgestrel Postmenopausal Osteoporosis 06-Jan-06 ibandronate sodium Primary Immunodeficiencies 09-Jan-06 (immune globulin subcutaneous Psoriasis 10-Jan-06 calcipotriene and betamethasone Gastrointestinal Stromal Tumors and Renal Carcinoma 26-Jan-06 sunitinib malate Type 1 and Type 2 Diabetes in Adults 27-Jan-06 insulin human Chronic Angina 27-Jan-06 ranolazine Exposure to Hepatitis B 30-Jan-06 (hepatitis B immune globulin Constipation 31-Jan-06 lubiprostone Seasonal Allergy Symptoms 01-Feb-06 desloratadine and pseudoephedrine Prevention of Rotavirus Gastroenteritis 03-Feb-06 rotavirus Diaper Dermatitis Complicated by Candidiasis 16-Feb-06 miconazole nitrate, zinc oxide and white petrolatum Prevention of Pregnancy 17-Feb-06 norethindrone acetate/ethinyl estradiol and ferrous fumarate Candidemia 17-Feb-06 anidulafungin Indication Approval date Molecule

25. Cost Of New Drug 800 Million Pill

28. To Make It More Complex Exclusivity Time is Eroding

29. .. And Productivity Does Not Seem to Be Improving

30. So.. What’s the Next BIG Thing in Healthcare??? Some Adventurous Prophecies...

33. Understanding The Value Chain First Where Does The R&D Money Go? 12% 15% 5% 9% 29% 5% 10% 4.5 % 8% 2.5% Synthesis Biology/Pharmaco Toxico/Safety Others Bioavailability Regulatory Formulation Phase I-III Phase IV Process Dvpt

34. Potential Value for India’s R&D Based Industry 12% 15% 5% 9% 29% 5% 10% 4.5% 8% 2.5% Synthesis Biology/Pharmaco Toxico/Safety Others Bioavailability Regulatory Formulation Phase I-III Phase IV Process Dvpt

35. T he C loning of P arent D rugs

37. Copy Cats Taking an Edge! Source: IMS 3Q / 2006 2 1991 5% 8% 79606 Losec 1 1996 18% 45% 298772 Risek Rank Yr of Launch Mkt. Share Growth Value+000 Brands 3 2002 12.70% 18% 165989 Roferon 1 2000 42.60% 65.30% 558717 Uniferon Rank Yr of Launch Mkt. Share Growth Value+000 Brands

38. Status of New Generic Launches in Pakistan Source: IMS 3Q / 2006 40 31 8 Macter 10 30 7 Searle 5 37 14 Highnoon 2 31 10 Hilton 4 38 7 Sami 1 27 16 Getz Rank Total Products New Launch in 8 Qtr Company

41. A Road Map for the Generic Developer

49. Now the CAD knows where is its target market - ASIA Obesity Hypertension Diabetes Smoking Genetics Lack of Physical Activity

54. IMS Status 14 Growth 5,596,848,000 Value 51422400 Units Total Cardio 3 Growth 354,366,000 Value 3,736,800 Units Total Nitrates 14 Growth 1,008,467,000 Value 13,859,700 Units Total Beta Blockers 12 Growth 817,938,000 Value 8,302,700 Units Total Calcium Antagonist (Plain)

55. IMS Status- Nitrates 57 10900 720 Bioglan Isotrate 15 13779 315 Barret Imdur 13 14112 1546 Biogenics AngiocardSR 27 14385 11065 GSK Angised 0 21795 644 Schwarz Isoket -22 22575 1042 Schwarz Elanton 10 36813 5642 Roche Ismo 9 52501 3322 Efroze Monis Range 22 53675 2969 EGIS Nitromint -14 47653 3368 Pharmax Sustac SR Nitrates GROWTH VALUE +000 UNITS+00 COMPANY PRODUCT

56. IMS Status- Beta Blockers 58 23,794 130,7 Roche Dimitone 56 25,356 176,4 Ferozsons Carveda 9 30,300 907,6 Nabiqasim Normitab 17 31,954 939,8 Zafa Zafnol -1 33,036 597,9 Zafa Atenolol 6 67,400 421,5 Novartis Mepresor 22 92,979 814,1 Almiral Blokium 18 106,890 1,164,0 Merck Concor 9 115,614 2,141,6 Zeneca Inderal 15 304,738 4,097,3 Zeneca Tenormin GROWTH VALUE +000 UNITS+00 COMPANY PRODUCT

57. IMS Status- Calcium Antagonist 20 12565 2068 sami Onato 28 14742 1032 MASS Amodip 21 21285 2540 Merck Lodopin 18 21366 10929 Zafa Zodip -22 22947 1309 Hilton Cardiosil 10 53663 3385 Bayer Adalat 14 70444 4073 Tanabe Herbessor 46 94616 15364 Searle Calan 11 108895 16372 Wilson Sofvasc 15 246379 10688 Pfizer Norvasc GROWTH VALUE +000 UNITS+00 COMPANY PRODUCT

58. Available Cardiac Energizer 20 36006 2300 Vastrel MR. 21 36417 2324 Vastrel 32 9077 683 Dinemic Growth Value Units Q4-2002 >999 39099 2312 60 58387 3544 11.1 8645 650 Growth Value Units Q4-2003 40 54674 3233 15 67219 4035 -17 7150 501 Growth Value Units Q4-2004 19 64894 3838 11 74656 4461 -3 6938 453 Growth Value Units Q4-2005 11 78222 4670 -8 6578 425 Growth Value Units Q1-2006

59. 65%

64. Pricing Ideas MRP: Rs. 240 per pack of 20’s TP: Rs. 204 per pack of 20’s Exfactory: Rs. 183.6 per pack of 20’s Exfactory per tab: 9.18 Rs.

66. Caution Check Patent Status

67. Raw Material Cost According to a rough Estimate, to maintain the profitability same as Dinemic, the RM of Ronalizine should be around 30$/Kg Caution

68. “ The single largest challenge facing drug developers — both pharmaceutical and biotechnology companies — is to contain R&D costs and reduce development times without compromising clinical test design. It’s a tall order.” Tufts Center Director, Dr. Kenneth I Kaitin